Analysts Issue Forecasts for Immunome FY2027 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Stock analysts at Lifesci Capital issued their FY2027 EPS estimates for shares of Immunome in a report released on Tuesday, May 12th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings of ($1.94) per share for the year. The consensus estimate for Immunome’s current full-year earnings is ($2.50) per share.

Several other analysts have also weighed in on IMNM. Wedbush reiterated an “outperform” rating and set a $31.00 target price on shares of Immunome in a research report on Thursday, January 15th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Truist Financial upgraded shares of Immunome to a “strong-buy” rating in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Finally, Stephens reduced their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.45.

Immunome Stock Performance

Shares of Immunome stock opened at $22.20 on Thursday. The firm’s 50-day simple moving average is $21.98 and its 200-day simple moving average is $21.14. Immunome has a twelve month low of $7.42 and a twelve month high of $27.65. The firm has a market cap of $2.51 billion, a P/E ratio of -9.33 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12.

Insider Transactions at Immunome

In other news, insider Jack Higgins sold 9,438 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the transaction, the insider directly owned 22,000 shares in the company, valued at approximately $476,080. This represents a 30.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 65,000 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. The trade was a 54.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after buying an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA increased its stake in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Immunome in the fourth quarter valued at approximately $30,710,000. Finally, Sofinnova Investments Inc. increased its stake in Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.